Extranodal NK/T-cell Lymphoma Clinical Trial
Official title:
A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients
The study aims to evaluate the efficacy and safety of VT-EBV-N (EBV-CTL) administration in ENKL patients after complete remission (CR). This is to prove the effect of VT-EBV-N (EBV-CTL) in prevention of ENKL relapse compared to placebo, by checking the primary endpoint of DFS rate (disease free survival, no relapse or death after randomization) at 2 years (103 weeks) for the last subject enrolled. 50% of the subjects will be administered VT-EBV-N (EBV-CTL), while the remaining subjects will be administered a placebo.
NK/T-cell lymphoma is a malignant tumor originating in NK cells and T lymphocytes. ENKL is associated with Epstein-Barr virus (EBV) infection and typically occurs in the nasal area, being termed ENKL, nasal type.EBV is a common virus in the herpes family. EBV infection in patients with lowered immunity such as those with Acquired Immune Deficiency Syndrome or those taking immunosuppressants after bone marrow transplant may induce lymphoproliferative diseases or cancer. VT-EBV-N (EBV-CTL) is a cytotoxicity T lymphocyte (CTL) targeting EBV expressed tumor cells indicated for ENKL. Antigen-presenting cells derived from the patient's own blood is used to activate T-cells in a test tube to recognize EBV, which are then expanded in vitro and infused into the patient's body. Targeted immunotherapy using EBV-CTL is a safe form of treatment that can improve long-term disease-free survival rates by boosting antitumor immunity without affecting other tissues apart from tumor cells. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04526834 -
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05377827 -
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04917250 -
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT06406556 -
Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL
|
Phase 2 | |
| Not yet recruiting |
NCT04337593 -
Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
|
Phase 2 | |
| Active, not recruiting |
NCT04414163 -
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
|
Phase 2 | |
| Not yet recruiting |
NCT05700448 -
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
|
Phase 3 | |
| Completed |
NCT03246750 -
B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03598959 -
Tofacitinib Combined With Chidamide in R/R ENKTCL
|
Phase 2 | |
| Recruiting |
NCT00725231 -
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
|
Phase 3 | |
| Recruiting |
NCT04554511 -
Prognostic Nomogram of Extranodal NK/T-cell Lymphoma
|
||
| Completed |
NCT03493451 -
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
|
Phase 2 | |
| Recruiting |
NCT04279379 -
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
|
Phase 2 | |
| No longer available |
NCT05131438 -
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
|